Safety of varying dosages of 7-valent pneumococcal protein conjugate vaccine in seniors previously vaccinated with 23-valent pneumococcal polysaccharide vaccine

Lisa A. Jackson; Kathleen M. Neuzil; Cynthia G. Whitney; Patty Starkovich; Maya Dunstan; Onchee Yu; Jennifer C. Nelson; Daniel R. Feikin; David K. Shay; James Baggs; Barb Carste; Moon H. Nahm; George Carlone

doi:10.1016/j.vaccine.2005.02.017

Safety of varying dosages of 7-valent pneumococcal protein conjugate vaccine in seniors previously vaccinated with 23-valent pneumococcal polysaccharide vaccine

Lisa A. Jackson, Kathleen M. Neuzil, Cynthia G. Whitney, Patty Starkovich, Maya Dunstan, Onchee Yu, Jennifer C. Nelson, Daniel R. Feikin, David K. Shay, James Baggs, Barb Carste, Moon H. Nahm, George Carlone

Research output: Contribution to journal › Article › peer-review

16 Scopus citations

Abstract

In a phase I/II dose escalation study, varying volumes (0.1 ml, 0.5 ml, 1.0 ml and 2.0 ml) of 7-valent pneumococcal conjugate vaccine (PCV) (Prevnar ^®) or 0.5 ml of 23-valent pneumococcal polysaccharide vaccine (PPV) were administered to 220 adults 70 through 79 years of age previously vaccinated with 0.5 ml PPV at age 65 years or above and at least 5 years previously. Fever was uncommon and did not vary by study group. The rate of local reactions increased with higher volumes of PCV and the rate following 2.0 ml of PCV was comparable to that following 0.5 ml PPV.

Original language	English (US)
Pages (from-to)	3697-3703
Number of pages	7
Journal	Vaccine
Volume	23
Issue number	28
DOIs	https://doi.org/10.1016/j.vaccine.2005.02.017
State	Published - May 25 2005
Externally published	Yes

Keywords

Conjugate vaccine
Pneumococcal vaccine
Vaccine safety

ASJC Scopus subject areas

Molecular Medicine
Immunology and Microbiology(all)
veterinary(all)
Public Health, Environmental and Occupational Health
Infectious Diseases

Access to Document

10.1016/j.vaccine.2005.02.017

Cite this

Jackson, L. A., Neuzil, K. M., Whitney, C. G., Starkovich, P., Dunstan, M., Yu, O., Nelson, J. C., Feikin, D. R., Shay, D. K., Baggs, J., Carste, B., Nahm, M. H., & Carlone, G. (2005). Safety of varying dosages of 7-valent pneumococcal protein conjugate vaccine in seniors previously vaccinated with 23-valent pneumococcal polysaccharide vaccine. Vaccine, 23(28), 3697-3703. https://doi.org/10.1016/j.vaccine.2005.02.017

Jackson, LA, Neuzil, KM, Whitney, CG, Starkovich, P, Dunstan, M, Yu, O, Nelson, JC, Feikin, DR, Shay, DK, Baggs, J, Carste, B, Nahm, MH & Carlone, G 2005, 'Safety of varying dosages of 7-valent pneumococcal protein conjugate vaccine in seniors previously vaccinated with 23-valent pneumococcal polysaccharide vaccine', Vaccine, vol. 23, no. 28, pp. 3697-3703. https://doi.org/10.1016/j.vaccine.2005.02.017

@article{93fe57898a914523a2c733042d90e197,

title = "Safety of varying dosages of 7-valent pneumococcal protein conjugate vaccine in seniors previously vaccinated with 23-valent pneumococcal polysaccharide vaccine",

abstract = "In a phase I/II dose escalation study, varying volumes (0.1 ml, 0.5 ml, 1.0 ml and 2.0 ml) of 7-valent pneumococcal conjugate vaccine (PCV) (Prevnar {\textregistered}) or 0.5 ml of 23-valent pneumococcal polysaccharide vaccine (PPV) were administered to 220 adults 70 through 79 years of age previously vaccinated with 0.5 ml PPV at age 65 years or above and at least 5 years previously. Fever was uncommon and did not vary by study group. The rate of local reactions increased with higher volumes of PCV and the rate following 2.0 ml of PCV was comparable to that following 0.5 ml PPV.",

keywords = "Conjugate vaccine, Pneumococcal vaccine, Vaccine safety",

author = "Jackson, {Lisa A.} and Neuzil, {Kathleen M.} and Whitney, {Cynthia G.} and Patty Starkovich and Maya Dunstan and Onchee Yu and Nelson, {Jennifer C.} and Feikin, {Daniel R.} and Shay, {David K.} and James Baggs and Barb Carste and Nahm, {Moon H.} and George Carlone",

note = "Funding Information: This study was supported by the Vaccine Safety Datalink contract with America's Health Insurance Plans, funded by the Centers for Disease Control and Prevention.",

year = "2005",

month = may,

day = "25",

doi = "10.1016/j.vaccine.2005.02.017",

language = "English (US)",

volume = "23",

pages = "3697--3703",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier BV",

number = "28",

}

TY - JOUR

T1 - Safety of varying dosages of 7-valent pneumococcal protein conjugate vaccine in seniors previously vaccinated with 23-valent pneumococcal polysaccharide vaccine

AU - Jackson, Lisa A.

AU - Neuzil, Kathleen M.

AU - Whitney, Cynthia G.

AU - Starkovich, Patty

AU - Dunstan, Maya

AU - Yu, Onchee

AU - Nelson, Jennifer C.

AU - Feikin, Daniel R.

AU - Shay, David K.

AU - Baggs, James

AU - Carste, Barb

AU - Nahm, Moon H.

AU - Carlone, George

N1 - Funding Information: This study was supported by the Vaccine Safety Datalink contract with America's Health Insurance Plans, funded by the Centers for Disease Control and Prevention.

PY - 2005/5/25

Y1 - 2005/5/25

N2 - In a phase I/II dose escalation study, varying volumes (0.1 ml, 0.5 ml, 1.0 ml and 2.0 ml) of 7-valent pneumococcal conjugate vaccine (PCV) (Prevnar ®) or 0.5 ml of 23-valent pneumococcal polysaccharide vaccine (PPV) were administered to 220 adults 70 through 79 years of age previously vaccinated with 0.5 ml PPV at age 65 years or above and at least 5 years previously. Fever was uncommon and did not vary by study group. The rate of local reactions increased with higher volumes of PCV and the rate following 2.0 ml of PCV was comparable to that following 0.5 ml PPV.

AB - In a phase I/II dose escalation study, varying volumes (0.1 ml, 0.5 ml, 1.0 ml and 2.0 ml) of 7-valent pneumococcal conjugate vaccine (PCV) (Prevnar ®) or 0.5 ml of 23-valent pneumococcal polysaccharide vaccine (PPV) were administered to 220 adults 70 through 79 years of age previously vaccinated with 0.5 ml PPV at age 65 years or above and at least 5 years previously. Fever was uncommon and did not vary by study group. The rate of local reactions increased with higher volumes of PCV and the rate following 2.0 ml of PCV was comparable to that following 0.5 ml PPV.

KW - Conjugate vaccine

KW - Pneumococcal vaccine

KW - Vaccine safety

UR - http://www.scopus.com/inward/record.url?scp=21044431601&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=21044431601&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2005.02.017

DO - 10.1016/j.vaccine.2005.02.017

M3 - Article

C2 - 15882530

AN - SCOPUS:21044431601

SN - 0264-410X

VL - 23

SP - 3697

EP - 3703

JO - Vaccine

JF - Vaccine

IS - 28

ER -

Safety of varying dosages of 7-valent pneumococcal protein conjugate vaccine in seniors previously vaccinated with 23-valent pneumococcal polysaccharide vaccine

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this